Will Novavax Stock Benefit From Johnson & Johnson’s Covid Vaccine Woes?
- Thursday, April 15, 2021, 7:16
- Market
- Add a comment
Novavax (NASDAQ: NVAX) stock rallied by over 10% after the U.S. Food and Drug Administration and the U.S. Centers for Disease Control paused the rollout of Johnson & Johnson’s Covid-19 vaccine in the U.S. following some rare, yet severe incidents of blood clotting.
About the Author
admin123 has written 23544 stories on this site.
